The available treatment options are not uniformly suitable for all patients with MTC and are dependent on the anatomical extent of the disease, serum level of Ctn and CEA, and genomic landscape of the tumor, among others [172,173,174,175,176]. This evidence concerns the gene CEACAM5 and medullary thyroid gland carcinoma.